Ascendis Pharma (NasdaqGS:ASND) is back on investor radar after a recent share price move, with the stock up 4.3% over the past week and 0.3% year to date.

The recent 7-day share price return of 7.31% and 1-day share price return of 4.34%, taking Ascendis Pharma to $246.14, point to momentum building after a relatively flat year-to-date share price return of 0.31%.

If this kind of move has you looking beyond a single stock, it could be a good moment to broaden your search with 35 healthcare AI stocks.

With Ascendis Pharma trading at $246.14, alongside an intrinsic discount figure and a price target gap, the key question is whether the recent momentum leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 28% Undervalued

At a last close of $246.14 against a narrative fair value of $342.08, the current price sits well below what the most followed storyline implies, and that gap is built on some very punchy growth assumptions.

Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies. This can add new royalty or collaboration streams alongside product sales and support earnings as R&D productivity improves.

Want to see what kind of revenue curve and margin profile sit behind that fair value, and how long term earnings power is being framed? The core of this narrative leans on steep top line growth, a sharp shift in profitability and a future earnings multiple that assumes investors are willing to pay up for that story.

Result: Fair Value of $342.08 (UNDERVALUED)

However, this hinges on YORVIPATH and TransCon CNP adoption meeting expectations, while rising commercial spend could pressure margins if revenue does not keep pace.

Another Take On Valuation

The multiple view pulls in the opposite direction to the narrative fair value. Ascendis Pharma trades on a P/E of 26.1x versus 17.8x for the US Biotechs industry and 12.6x for peers, so the stock looks expensive on earnings. This raises the question of how much good news is already priced in.

For a closer look at how that earnings based view stacks up against a full valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern feels familiar, use it as a prompt to act now by reviewing the full picture for yourself with 3 key rewards and 3 important warning signs

Looking for more investment ideas?

Do not stop with a single stock when there are tools built to surface fresh opportunities that match the way you like to invest.

• Target potential turnaround stories by scanning 25 elite penny stocks with strong financials that already show stronger financials than many would expect from low priced shares.
• Zero in on quality at a reasonable price by using the 51 high quality undervalued stocks to spot companies combining solid fundamentals with attractive valuations.
• Prioritise resilience by checking the 71 resilient stocks with low risk scores for stocks that score well on financial strength and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.